EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

This study is designed to assess the effects of AZD 2624 in patients with schizophrenia

Phase IIA study in patients with schizophrenia

Research Site

A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD2624 in Adult Schizophrenia Patients

PANSS total score, sum of 30 item scores (each on a 0 to 7 scale), assesses positive and negative symptoms of psychopathology on a continuous scale from 0 (the best) to 210 (the worst). Day 28 value was calculated using last observation carried forward (LOCF).  Change from baseline was calculated as Day 28 value minus baseline value.

Age Continuous

Gender, Male/Female

Positive and Negative Syndrome Scale (PANSS) total score change from baseline

Overall Study

Patients were screened  up to 21 days, and admitted to the Clinical Research Unit (CRU) for a maximum of 2 days until eligibility was determined.  Once eligibility was determined, patients currently on medication entered a 7 days washout period, patients not currently on medication had a 3 day washout, prior to randomization to study medication.

Arms	Assigned Interventions
Experimental: AZD2624 AZD2624 40 mg	Drug: AZD2624 Oral Suspension
Other: Olanzapine Olanzapine 15 mg	Drug: Olanzapine PO BID Other Name: Zyprexa
Placebo Comparator: Placebo Matching Placebo	-

Phase IIA study in patients with schizophrenia

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=245&filename=CSR-D0970C00004.pdf

CSR-D0970C00004.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator